Gabitril Potential In Anxiety Is Aided By Favorable Side Effect Profile, Cephalon Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to add an indication for generalized anxiety disorder by 2006. Cephalon expects anti-epileptic Gabitril will generate $100 mil. in 2004; 70% of use is for neuropsychiatric disorders.